Cetuximab

(Erbitux®)

Cetuximab

Drug updated on 11/16/2023

Dosage FormInjection (intravenous: 100 mg/50 mL (2 mg/mL) or 200 mg/100 mL (2 mg/mL))
Drug ClassEpidermal growth factor receptor (EGFR) antagonist
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.
  • For the treatment of recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.
  • For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy
  • For the treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test: in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.
  • For the treatment of BRAF V600E mutation-positive metastatic colorectal cancer (CRC): in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.